{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:47:18Z","timestamp":1784933238507,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.critrevonc.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T20:35:00Z","timestamp":1518122100000},"page":"51-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Hormone replacement therapy in cancer survivors: Utopia?"],"prefix":"10.1016","volume":"124","author":[{"given":"Roberto","family":"Angioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Armento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Capriglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Plotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Scaletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Montera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovan Battista","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Benedetti Panici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9484","key":"10.1016\/j.critrevonc.2018.02.005_bib0005","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(05)67063-8","article-title":"Endometrial cancer","volume":"366","author":"Amant","year":"2005","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.critrevonc.2018.02.005_bib0010","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","article-title":"Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women\u2019s health initiative randomized trial","volume":"90","author":"Anderson","year":"2003","journal-title":"JAMA"},{"issue":"9084","key":"10.1016\/j.critrevonc.2018.02.005_bib0015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","article-title":"Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer","volume":"350","author":"Anon","year":"1997","journal-title":"Lancet"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2018.02.005_bib0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jog.12360","article-title":"Annual report of Gynecologic Oncology Committee, Japan Society ofObstetrics and Gynecology, 2013","volume":"40","author":"Aoki","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.02.005_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1525-1438.2006.00526.x","article-title":"Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?","volume":"16","author":"Ayhan","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.02.005_bib0030","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000055319","article-title":"Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates","volume":"60","author":"Beckmann","year":"2001","journal-title":"Oncology"},{"issue":"9382","key":"10.1016\/j.critrevonc.2018.02.005_bib0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone replacement therapy in the Million Women Study","volume":"362","author":"Beral","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.02.005_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM198908033210505","article-title":"The risk of breast cancer after estrogen and estrogen-progestin replacement","volume":"321","author":"Bergkvist","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/01443615.2012.668579","article-title":"Safety of hormone replacement therapy in gynaecological cancer survivors","volume":"32","author":"Biliatis","year":"2012","journal-title":"J. Obstet. Gynaecol."},{"issue":"October (28)","key":"10.1016\/j.critrevonc.2018.02.005_bib0055","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2007.10.6815","article-title":"Relationship between epidemiologic risk factors and breast cancer recurrence","volume":"25","author":"Brewster","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"October","key":"10.1016\/j.critrevonc.2018.02.005_bib0060","article-title":"Role of paroxetine in the management of hot flashes in gynecological cancer survivors: results of the first randomized single-center controlled trial","volume":"14","author":"Capriglione","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.02.005_bib0065","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","article-title":"Estrogen replacement in surgical stage I and II endometrial cancer survivors","volume":"175","author":"Chapman","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0070","first-page":"2003","article-title":"Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial","volume":"2893243","author":"Chlebowski","year":"2016","journal-title":"JAMA"},{"issue":"May (9980)","key":"10.1016\/j.critrevonc.2018.02.005_bib0075","first-page":"1835","article-title":"Menopausal hormone use andovarian cancer risk: individual participant meta-analysis of 52 epidemiologicalstudies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.02.005_bib0080","first-page":"77","article-title":"The American College of Obstetricians and Gynecologists ACOG committee opinion: tamoxifen and endometrial cancer","volume":"73","author":"Committee on Gynecologic Practice","year":"2001","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.02.005_bib0085","first-page":"326","article-title":"Estrogen replacement therapy in the patient treated for endometrial cancer","volume":"67","author":"Creasman","year":"1986","journal-title":"Obstet. Gynecol."},{"issue":"January\u2013February (1)","key":"10.1016\/j.critrevonc.2018.02.005_bib0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21320","article-title":"Breast cancer statistics, 2015: Convergence of incidence rates between black and white women","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0095","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.GME.0000061806.76067.E9","article-title":"Estrogen replacement therapy in breast cancer survivors: a matched-controlled series","volume":"10","author":"Decker","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-200012000-00001","article-title":"Breast cancer survival and hormone replacement therapy: a cohort analysis","volume":"23","author":"DiSaia","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.5694\/j.1326-5377.2002.tb04835.x","article-title":"Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality","volume":"177","author":"Durna","year":"2002","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0110","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2623::AID-CNCR19>3.0.CO;2-O","article-title":"Epithelial ovarian carcinoma in the reproductive age group","volume":"85","author":"Duska","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/bmj.302.6771.259","article-title":"Hormone replacement therapy and survival after surgery for ovarian cancer","volume":"302","author":"Eeles","year":"1991","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","article-title":"Hormone replacement therapy after breast cancer: 10\u202fyear follow up of the Stockholm randomised trial","volume":"49","author":"Fahlen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0125","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1055\/s-0031-1280437","article-title":"Breast cancer risk \u2013 genes, environment and clinics","volume":"71","author":"Fasching","year":"2011","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors:a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3109\/13697137.2013.806471","article-title":"Estrogen therapy in gynecological cancer survivors","volume":"16","author":"Guidozzi","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2013.10.009","article-title":"The Women\u2019s Health Initiative trial and related studies: 10 years later: a clinician\u2019s view","volume":"142","author":"Gurney","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0145","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/CEJ.0b013e328355ec22","article-title":"Hormone replacement therapy and prognosis in ovarian cancer patients","volume":"22","author":"Hein","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.02.005_bib0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJM197608192950801","article-title":"Menopausal estrogens and breast cancer","volume":"295","author":"Hoover","year":"1976","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0160","series-title":"SEER Cancer Statistics Review, 1975\u20132006","year":"2009"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0165","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.12669\/pjms.296.3788","article-title":"Age-specific incidence rate change at breast cancer and its different histopathologic subtypes in Iran and Western countries","volume":"29","author":"Hosseini","year":"2013","journal-title":"Pak. J. Med. Sci."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0170","series-title":"Endometrial Cancer Treatment Guidelines","author":"Japan Society of Gynecologic Oncology","year":"2013"},{"issue":"4314","key":"10.1016\/j.critrevonc.2018.02.005_bib0175","first-page":"2003","article-title":"Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population","volume":"21","author":"Kerlikowske","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.02.005_bib0180","doi-asserted-by":"crossref","first-page":"248","DOI":"10.6004\/jnccn.2014.0025","article-title":"Uterine neoplasms, version 1.2014","volume":"12","author":"Koh","year":"2014","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/gyno.2000.5731","article-title":"Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix","volume":"77","author":"Lacey","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0960-0760(94)90019-1","article-title":"The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines","volume":"50","author":"Langdon","year":"1994","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0195","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/ijc.28741","article-title":"17beta-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo","volume":"135","author":"Laviolette","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.02.005_bib0200","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(90)90171-G","article-title":"Estrogen replacement therapy following treatment for stage I endometrial carcinoma","volume":"36","author":"Lee","year":"1990","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0205","first-page":"837","article-title":"Estrogen and combined hormone therapy for women after genital malignancies","volume":"49","author":"Levgur","year":"2004","journal-title":"J. Reprod. Med."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3","article-title":"Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma","volume":"77","author":"Li","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0215","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3892\/ol.2011.461","article-title":"Impact of postoperative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy","volume":"3","author":"Li","year":"2012","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.02.005_bib0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2015.07.109","article-title":"Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis","volume":"139","author":"Li","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"205","key":"10.1016\/j.critrevonc.2018.02.005_bib0225","first-page":"211","article-title":"The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer","volume":"58","author":"Lower","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0230","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/ijc.22218","article-title":"Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival","volume":"119","author":"Mascarenhas","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0235","first-page":"420","article-title":"Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis","volume":"43","author":"McCluggage","year":"2011","journal-title":"Pathology (Phila.)"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0240","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/CCO.0b013e32832efc5b","article-title":"Managing menopausal symptoms after gynecological cancer","volume":"21","author":"Michaelson-Cohen","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/jnci\/93.10.754","article-title":"Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality","volume":"93","author":"O'Meara","year":"2001","journal-title":"J. Natl. Cancer Inst."},{"issue":"5570","key":"10.1016\/j.critrevonc.2018.02.005_bib0250","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1069675","article-title":"Broken limits to life expectancy","volume":"296","author":"Oeppen","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0255","first-page":"651","article-title":"Profiles of women age 30\u201339 and age less than 30 with epithelial ovarian cancer","volume":"81","author":"Plaxe","year":"1993","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0260","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormone replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0265","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.ejca.2005.07.015","article-title":"Vaginal oestrogen therapy after breast cancer: is it safe?","volume":"41","author":"Ponzone","year":"2005","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.02.005_bib0270","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/IGC.0b013e31821bd473","article-title":"Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Soci\u2019t\u2019 Fran\u00e9aise d\u00e7Oncologie Gyn\u2019cologique","volume":"21","author":"Querleu","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0275","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/1097-0142(19940215)73:4<1245::AID-CNCR2820730419>3.0.CO;2-5","article-title":"National survey of ovarian carcinoma XII. Epithelial ovarian malignancies in women less than or equal to 25 years of age","volume":"73","author":"Rodriguez","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0280","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/oxfordjournals.aje.a117518","article-title":"Estrogen replacement therapy and fatal ovarian cancer","volume":"141","author":"Rodriguez","year":"1995","journal-title":"Am. J. Epidemiol."},{"issue":"16","key":"10.1016\/j.critrevonc.2018.02.005_bib0285","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jama.1980.03300420019018","article-title":"A case-control study of menopausal estrogen therapy and breast cancer","volume":"243","author":"Ross","year":"1980","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2018.02.005_bib0290","first-page":"84","article-title":"The endometrium: effects of estrogen and estrogenprogestogen replacement therapy","volume":"39","author":"Samsioe","year":"1994","journal-title":"Int. J. Fertil. Menopausal Stud."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0295","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0305","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.maturitas.2009.11.017","article-title":"Hormone replacement after gynaecological cancer","volume":"65","author":"Singh","year":"2010","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.02.005_bib0310","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: a matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0315","first-page":"1","article-title":"The 2012 hormone therapy position statement of the North American menopause society menopause","volume":"19","author":"The North American Menopause Society (NAMS)","year":"2012","journal-title":"Menopause"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0320","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1634\/theoncologist.2007-0234","article-title":"Should urogenital atrophy in breast cancer survivors be treated with topical estrogens?","volume":"13","author":"Trinkaus","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0325","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00042192-200101000-00012","article-title":"Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival","volume":"8","author":"Ursic-Vrscaj","year":"2001","journal-title":"Menopause"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0330","first-page":"538","article-title":"Hormonal replacement therapy in ovarian cancer survivors: a survey among Greek gynecologists","volume":"32","author":"Vavilis","year":"2011","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5122(00)00150-X","article-title":"Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies","volume":"36","author":"Verheul","year":"2000","journal-title":"Maturitas"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0340","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00198-003-1408-1","article-title":"Early menopause: increased fracture risk at older age","volume":"14","author":"van Der Voort","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0345","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/jama.1979.03300030033017","article-title":"Endometrial cancer in relation to patterns of menopausal estrogen use","volume":"242","author":"Weiss","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0350","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/13697137.2013.806472","article-title":"The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China","volume":"16","author":"Wen","year":"2013","journal-title":"Climacteric"},{"issue":"May (9980)","key":"10.1016\/j.critrevonc.2018.02.005_bib0355","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0140-6736(14)62458-2","article-title":"Hormone therapy: short-term relief, long-term consequences","volume":"385","author":"Wentzensen","year":"2015","journal-title":"Lancet"},{"issue":"October (5)","key":"10.1016\/j.critrevonc.2018.02.005_bib0360","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10147-015-0808-5","article-title":"How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey","volume":"20","author":"Yokoyama","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.02.005_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0020-7292(96)02719-1","article-title":"Diagnosis and management of malignant germ cell ovarian tumors in young females","volume":"55","author":"Zalel","year":"1996","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"June (11)","key":"10.1016\/j.critrevonc.2018.02.005_bib0370","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4103\/0366-6999.182835","article-title":"Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma","volume":"129","author":"Zhang","year":"2016","journal-title":"Chin. Med. J. (Engl.)"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817302676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T17:01:05Z","timestamp":1570726865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817302676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":74,"alternative-id":["S1040842817302676"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.005","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone replacement therapy in cancer survivors: Utopia?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}